Stratified medicine with eplerenone for myocardial infarction or injury and no obstructive coronary arteries: A registry-based basket trial.
Robert Sykes, Dylan Tan, Gemma McKinley et al.
✦ AI-curated · Sources linked
In 30 seconds
This multicenter, registry-based randomized controlled trial investigates the prevalence of coronary microvascular dysfunction in patients with suspected MINOCA and evaluates the efficacy of eplerenone treatment. Among patients with an index of coronary microvascular resistance (IMR) ≥ 25, the primary outcome will assess changes in NT-proBNP levels over 6 months. The study aims to provide insights into targeted therapies for this population.
Key findings
- Approximately 1 in 9 patients with acute coronary syndrome present with MINOCA.
- Patients with IMR ≥ 25 will be randomized to receive eplerenone or standard care.
- The primary outcome measures changes in NT-proBNP at baseline, 1 month, and 6 months.
Why it matters
Understanding the prevalence of coronary microvascular dysfunction and the potential benefits of eplerenone could lead to improved management strategies for patients with MINOCA, a condition currently lacking effective evidence-based treatments.